Figure 4.

ΔORF3-E mNG virion-based high-throughput neutralization and antiviral testing

(A) Assay scheme in a 96-well format.

(B) Correlation analysis of NT₅₀ values between the ΔORF3-E mNG virion assay and plaque-reduction neutralization test (PRNT). The Pearson correlation coefficiency R² and p values (two-tailed) are indicated.

(C) Neutralization curves. Representative curves are presented for one negative and three positive sera. The means and standard deviations from two independent experiments are shown.

(D) EC₅₀ of human mAb14 against ΔORF3-E mNG virion infecting Vero CCL81 cells. The mean ± standard deviations from four independent experiments are indicated.

(E) EC₅₀ of Remdesivir against ΔORF3-E mNG virion infecting A549-hACE2 cells.

(F) EC₅₀ of Remdesivir against ΔORF3-E mNG virion on Vero CCL81 cells. For (E) and (F), the mean ± standard deviations from three independent experiments are indicated. The four-parameter dose-response curve was fitted using the nonlinear regression method.